Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
3 INNOVATION
Cosentyx® - rapid and sustained efficacy in Hidradenitis Suppurativa
up to 52 weeks
High unmet need
-1 in 100
~95%
~50%
Cosentyx® Ph3 data (SUNSHINE, SUNRISE)4
Week 16
Cosentyx
Week 52
☐ Rapid
relief
from pain,
flares, lesions,
Low Dose
High Dose
while improving
quality of life
Low Dose
1:1
High Dose
Sustained up to 52 weeks5
people affected
by HS1
eligible patients
not on biologic²
biologic-treated
patients lose
response³
moderate to severe
hidradenitis suppurativa
Secukinumab Low Dose
Secukinumab
High Dose
1:1:1
Placebo
The primary endpoint is the HiSCR at Week 16
HiSCR response: At least a 50% decrease in abscess
and Inflammatory Nodule count with no increase in the
number of abscesses and/or draining tunnels
response
Favorable
reinforced
safety
across 5
systemic
conditions
HS
Hidradenitis Suppurativa
HiSCR - Hidradenitis Suppurativa Clinical Response 1. MedLine Plus. Hidradenitis suppurativa [online] [Last accessed: Oct 2022]. 2. G6 market estimations based on IQVIA PADDS 2021.
3. Kimball A, et al. N Engl J Med. 2016;375:422-434. 4. Kimball A, et al. LB-3549 presented at EADV Congress 2022. 5. Topline results based on interim analysis where 95% of Ph3 study patients completed or discontinued by Week 52.
15 Investor Relations | Q3 2022 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation